Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million by selling 3,375,000 shares at $4.00 per share on the NYSE American exchange.

Recursion Pharmaceuticals presented Phase 1/2 data on REC-617, a CDK7 inhibitor, at an AACR Special Conference, showcasing its potential in treating advanced solid tumors.

Vivos Inc. has begun its first human clinical trial in India for RadioGel® Precision Radionuclide Therapy™ targeting cancerous lymph nodes.

Lipella Pharmaceuticals received U.S. Patent No. 12,138,345 for its liposomal drug delivery platform, enhancing targeted therapeutic agent delivery.

McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA.

Ultragenyx presented positive Phase 1/2 data for GTX-102, an antisense oligonucleotide targeting Angelman syndrome, at the FAST Global Science Summit.

Elite Pharmaceuticals has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules, offering seven strengths from 10 mg to 70 mg.

Milestone Pharmaceuticals received a Notice of Allowance from the USPTO for a new patent covering the repeat dose regimen of etripamil nasal spray, extending potential IP protection to July 2042.

The FDA granted Breakthrough Therapy Designation to Mirum Pharmaceuticals' volixibat for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).

ARIAD Pharmaceuticals is pushing forward with the development and approval of its new cancer drug, Ponatinib, aimed at treating resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. With promising clinical trial results and a rolling submission for New Drug Application completed, ARIAD seeks accelerated approval from the FDA and EMA, projecting significant market potential.

Avadel Pharmaceuticals reported $50.0 million in net revenue from LUMRYZ sales in Q3 2024, marking substantial growth in the narcolepsy treatment market.

ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Estradiol Gel, 0.06%, a generic version of EstroGel.

Acurx Pharmaceuticals announced positive Phase 2 trial results for ibezapolstat in treating C. difficile Infection (CDI), demonstrating a 96% clinical cure rate across Phase 2a and 2b trials.

Agenus Inc. is facing a class action lawsuit on behalf of investors who purchased securities between January 23, 2023, and July 17, 2024.

Lasofoxifene demonstrated a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting.

McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA.

McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA.

A U.S. District Court has affirmed the FDA's approval of Avadel Pharmaceuticals' LUMRYZ for treating cataplexy and excessive daytime sleepiness in adults with narcolepsy.

CytoDyn's leronlimab sees renewed progress with the FDA lifting its clinical hold in March 2024, enabling the advancement of clinical trials.

IDEAYA Biosciences focuses on precision medicine in oncology, highlighted by a strong pipeline of product candidates and collaborations with major pharmaceutical companies.